Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds.
In a double-blind, placebo-controlled study, patients with naturally occurring common colds of less than or equal to 48 h duration were randomly assigned to receive nasal sprays of recombinant alfa-2b interferon at 10 or 20 MU/day or placebo four times per day for 5 days. The 10-MU (n = 74), 20-MU (...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1988
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC172139/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2834996/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.32.2.224 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|